Stockscreener 앱 받기
15.91
3.40%
-0.56
시간 외 거래:
16.46
0.55
+3.46%
Odyssey Therapeutics Inc 주식(ODTX)의 최신 뉴스
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Enterprise value to EBIT forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - MarketBeat
Form 8K ODYSSEY THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash - TradingView
Odyssey Therapeutics (NASDAQ: ODTX) details I&I pipeline, OD-001 data and cash - Stock Titan
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P TMI Index - marketscreener.com
Odyssey Therapeutics, Inc. (ODTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) - The Globe and Mail
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
TD Cowen Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating - Moomoo
ODTX Reiterated by Oppenheimer -- Price Target Maintained at $40 - GuruFocus
Oppenheimer Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Odyssey Therapeutics: Q1 Earnings Snapshot - AOL.com
Odyssey Therapeutics, Inc. 2026 Q1 10-Q Report: Clinical Progress, Risk Factors, and Financial Overview - Minichart
Odyssey Therapeutics Q1 EPS $(6.77) misses $(1.13) estimate - scanx.trade
Odyssey Therapeutics reports Q1 2026: $38.3M net loss, $464.4M pro forma cash to fund into H2 2028 - TradingView
Odyssey Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(6.77) — 10-Q Summary - TradingView
ODTX: Strong clinical progress and IPO proceeds position the company for late-stage development - TradingView
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Odyssey Therapeutics (Nasdaq: ODTX) posts Q1 loss but secures $464M cash - Stock Titan
Odyssey Therapeutics reports positive OD-001 data and $464.4M cash position - scanx.trade
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics Reports Positive Phase 2a Proof-of-Concept Data for OD-001 in Ulcerative Colitis and Q1 2026 Financial Results - Quiver Quantitative
Odyssey Therapeutics sees ulcerative colitis signal in Phase 2a trial - Stock Titan
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wedbush Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
Anthony W. Opipari Net Worth (2026) - GuruFocus
Aranicki Ksenija Pavletic Net Worth (2026) - GuruFocus
Todd Collin M Net Worth (2026) - GuruFocus
Natalie Dales Net Worth (2026) - GuruFocus
Gary D Glick Net Worth (2026) - GuruFocus
ODTXOdyssey Therapeutics Inc Stock Price and Quote - Finviz
FMR LLC discloses 4.58M-share stake in Odyssey Therapeutics (ODTX) - Stock Titan
Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
ODTX Technical Analysis & ETF Price Forecast - Intellectia AI
Latest ODTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
ODTX Initiates Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
ODTX Initiates Coverage by JP Morgan -- Price Target Set at $26 - GuruFocus
ODTX Initiated Coverage by Cantor Fitzgerald -- Rated Overweight - GuruFocus
ODTX Initiates Coverage by Wedbush -- Price Target Announced at $30 - GuruFocus
Odyssey Therapeutics (ODTX) Rated Outperform with $30 Target - GuruFocus
ODTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
1.17%
2.48%
자본화:
|
볼륨(24시간):